摘要
[目的]观察非那雄胺联合坦洛新治疗BPH伴CP的临床疗效。[方法]选择BPH伴CP患者40例,口服非那雄胺(5mg/d)和坦洛新(0.2mg/d)3个月,在治疗前和治疗3个月后分别检查国际前列腺症状评分(IPSS)、尿流率、残余尿量、前列腺体积、前列腺液常规等指标。[结果]治疗后IPSS平均降低27.8%,最大尿流率平均升高37.0%,残余尿量平均减少39.4%,前列腺体积平均缩小18.4%,前列腺液中白细胞计数平均减少38.9%。前列腺液检查好转率60.0%,其中前列腺体积≥40ml组和<40ml组的前列腺液检查好转率分别为70.8%及43.7%,两组间比较差异有统计学意义(P<0.05)。[结论]非那雄胺联合坦洛新可有效治疗伴CP的BPH患者,对前列腺体积较大者效果更好。
[Objective]To observe the clinical efficacy of finasteride combined Tamsulosin on benign prostatic hyperplasia(BPH) with chronic prostatitis(CP).[Methods] 40 patients with BPH and CP had received oral administ ration of finasteride(5mg/d) and Tamsulosin(0.2mg/d) for 3 months.IPSS,urine flow rate,residual urine volume,prostatic volumeand expressed prostatic secretion(EPS) were detected before and after treatment.[Results] After treatment,maximalurine flow rate increased by 37.0%,but IPSS,residual urine volume,prostatic volume and leucocyte count in EPS decreased by 27.8%,39.4%,18.4% and 38.9% on average respectively.Total improvement rate of EPS examination was 60.0%,but the improvement rate in patients with prostatic volume ≥40ml was superior to that in patients with prostatic volume < 40ml(70.8% vs 43.7%).[Conclusion] Combined use of inasteride and Tamsulosin is effective for treating patients with BPH and CP,especially for those with bigger prostate.
出处
《浙江中医药大学学报》
CAS
2011年第2期191-192,共2页
Journal of Zhejiang Chinese Medical University
关键词
前列腺炎
前列腺增生
非那雄胺
坦洛新
prostatitis
prostatic hyperplasia
finasteride
Tamsulosin
